13 Papers
17 Citations
Edina Wang is an academic researcher from Harry Perkins Institute of Medical Research. The author has contributed to research in topics: Gene & Triple-negative breast cancer. The author has an hindex of 7, co-authored 13 publications. Previous affiliations of Edina Wang include University of Western Australia.
Chat about Author
Papers
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
Ciara Duffy,Anabel Sorolla,Anabel Sorolla,Edina Wang,Edina Wang,Emily Golden,Emily Golden,Eleanor A. Woodward,Eleanor A. Woodward,Kathleen Davern,Kathleen Davern,Diwei Ho,Elizabeth K. M. Johnstone,Elizabeth K. M. Johnstone,Elizabeth K. M. Johnstone,Kevin D. G. Pfleger,Andrew Redfern,K. Swaminathan Iyer,Boris Baer,Pilar Blancafort +19 more
- 01 Sep 2020
TL;DR: It is demonstrated that honeybee venom and its major component melittin potently induce cell death, particularly in the aggressive triple-negative and HER2-enriched breast cancer subtypes.
Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics
Anabel Sorolla,Edina Wang,Emily Golden,Ciara Duffy,Sónia Troeira Henriques,Andrew Redfern,Pilar Blancafort +6 more
TL;DR: Recent advances for the selective inhibition of major cancer oncoproteins via iPep approaches are outlined and the development of multimodal peptides to overcome limitations of the first generations of iPeps are discussed.
Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides
Anabel Sorolla,Anabel Sorolla,Edina Wang,Tristan D. Clemons,Cameron W. Evans,Janice Hc Plani-Lam,Emily Golden,Ben Dessauvagie,Andrew Redfern,K. Swaminathan-Iyer,Pilar Blancafort,Pilar Blancafort +11 more
TL;DR: A targeted nanoformulation for docetaxel-PGMA-PAA-nanoparticles and interference peptides designed to specifically inhibit EN1 (EN1-iPeps) significantly reduced TNBC growth both in vitro and in vivo without showing toxicity.
46
From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds
Edina Wang,Maria Alba Sorolla,Priya Darshini Gopal Krishnan,Anabel Sorolla +3 more
- 06 Feb 2020
TL;DR: This review outlines the most promising marine bioactives that have been investigated in cancer models and/or tested in patients as anticancer agents and describes the current state of development of anticancer marine compounds.
46
Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment
TL;DR: The conjugation of protein and peptides can improve tumor homing of nanoparticles, increase cellular penetration and attack specific drivers and vulnerabilities of the breast cancer cell to promote tumor cytotoxicity while reducing secondary effects in healthy tissues.
29